Ikervis Special Precautions

IKERVIS has not been studied in patients with a history of ocular herpes and should therefore be used with caution in such patients.
Contact lenses: Patients wearing contact lenses have not been studied. Careful monitoring of patients with severe keratitis is recommended. Contact lenses should be removed before instillation of the eye drops at bedtime and may be reinserted at wake-up time.
Concomitant therapy: There is limited experience with IKERVIS in the treatment of patients with glaucoma. Caution should be exercised when treating these patients concomitantly with IKERVIS, especially with beta-blockers which are known to decrease tear secretion.
Effects on the immune system: Medicinal products, which affect the immune system, including ciclosporin, may affect host defences against infections and malignancies. Co-administration of IKERVIS with eye drops containing corticosteroids could potentiate the effects of IKERVIS on the immune system (see Interactions).
Excipient: IKERVIS contains cetalkonium chloride which may cause eye irritation.
Effects on ability to drive and use machines: IKERVIS has moderate influence on the ability to drive and use machines.
This medicinal product may induce temporary blurred vision or other visual disturbances which may affect the ability to drive or use machines (see Adverse Reactions). Patients should be advised not to drive or use machines until their vision has cleared.